
Robert N Young

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6336509/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein. STAR Protocols, 2022, 3, 101258.	0.5	2
2	Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells inÂvivo. Molecular Therapy, 2022, 30, 3034-3051.	3.7	10
3	Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions. ACS Pharmacology and Translational Science, 2021, 4, 908-925.	2.5	2
4	Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta. Bone, 2021, 145, 115867.	1.4	3
5	Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator. IScience, 2021, 24, 102542.	1.9	29
6	E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis. Nature Cell Biology, 2021, 23, 796-807.	4.6	38
7	Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry, 2021, 64, 14968-14982.	2.9	9
8	Achieving enhanced bone regeneration using monetite granules with bone anabolic drug conjugates (C3 and C6) in rat mandibular defects. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2020, 108, 2670-2680.	1.6	8
9	Improved bone regeneration using bone anabolic drug conjugates (C3 and C6) with deproteinized bovine bone mineral as a carrier in rat mandibular defects. Journal of Periodontology, 2020, 91, 1521-1531.	1.7	1
10	In Vivo Bone Effects of a Novel Bisphosphonateâ€EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model. JBMR Plus, 2019, 3, e10237.	1.3	8
11	A Novel Anabolic Conjugate (C3) in the Matrix of Dicalcium Phosphate Onlay Block Grafts for Achieving Vertical Bone Augmentation: An Experimental Study on Rabbit Calvaria. International Journal of Oral and Maxillofacial Implants, 2019, 34, e51-e63.	0.6	7
12	Targeting therapeutics to bone by conjugation with bisphosphonates. Current Opinion in Pharmacology, 2018, 40, 87-94.	1.7	31
13	A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4B. Scientific Reports, 2018, 8, 11653.	1.6	33
14	Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del. Molecular Pharmacology, 2018, 94, 917-925.	1.0	30
15	Synthesis and characterization of a photoaffinity labelling probe based on the structure of the cystic fibrosis drug ivacaftor. Tetrahedron, 2018, 74, 5528-5538.	1.0	6
16	Inhibiting the Core Autophagy Enzyme ATG4B with Novel Drugs Sensitizes Resistant Leukemic Stem/Progenitor Cells to Standard Targeted Therapy. Blood, 2018, 132, 933-933.	0.6	2
17	Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis. Journal of Medicinal Chemistry, 2017, 60, 7012-7028.	2.9	20
18	Further investigation of inhibitors of MRSA pyruvate kinase: Towards the conception of novel antimicrobial agents. European Journal of Medicinal Chemistry, 2017, 125, 1-13.	2.6	19

#	Article	IF	CITATIONS
19	Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. Molecular Cancer Therapeutics, 2016, 15, 2936-2945.	1.9	24
20	In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss. Osteoporosis International, 2016, 27, 797-808.	1.3	8
21	Development of fluorescent peptide substrates and assays for the key autophagy-initiating cysteine protease enzyme, ATG4B. Bioorganic and Medicinal Chemistry, 2015, 23, 3237-3247.	1.4	35
22	Determination of the Rat in Vivo Pharmacokinetic Profile of a Bone-Targeting Dual-Action Pro-Drug for Treatment of Osteoporosis. Bioconjugate Chemistry, 2015, 26, 1095-1103.	1.8	12
23	The promise and peril of chemical probes. Nature Chemical Biology, 2015, 11, 536-541.	3.9	698
24	Precision autophagy: Will the next wave of selective autophagy markers and specific autophagy inhibitors feed clinical pipelines?. Autophagy, 2015, 11, 1949-1952.	4.3	17
25	Novel EP4 Receptor Agonist-Bisphosphonate Conjugate Drug (C1) Promotes Bone Formation and Improves Vertebral Mechanical Properties in the Ovariectomized Rat Model of Postmenopausal Bone Loss. Journal of Bone and Mineral Research, 2015, 30, 670-680.	3.1	23
26	Development of Fluorescent Substrates and Assays for the Key Autophagy-Related Cysteine Protease Enzyme, ATG4B. Assay and Drug Development Technologies, 2014, 12, 176-189.	0.6	31
27	Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer. Chemistry and Biology, 2014, 21, 1476-1485.	6.2	59
28	Discovery and optimization of a new class of pyruvate kinase inhibitors as potential therapeutics for the treatment of methicillin-resistant Staphylococcus aureus infections. Bioorganic and Medicinal Chemistry, 2014, 22, 1708-1725.	1.4	35
29	Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1 <i>H</i> -benzimidazole Derivatives. Journal of Medicinal Chemistry, 2013, 56, 1136-1148.	2.9	81
30	Cheminformatics-Driven Discovery of Selective, Nanomolar Inhibitors for Staphylococcal Pyruvate Kinase. ACS Chemical Biology, 2012, 7, 350-359.	1.6	23
31	Optimization and structure–activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents. Bioorganic and Medicinal Chemistry, 2012, 20, 7069-7082.	1.4	25
32	Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis. Bioorganic and Medicinal Chemistry, 2012, 20, 2131-2140.	1.4	39
33	Synthesis of a tritiumâ€labeled photoâ€affinity probe based on an atypical leukotriene biosynthesis inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 43-50.	0.5	6
34	Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 920-923.	1.0	36
35	Inhibition of Autophagosome Formation by the Benzoporphyrin Derivative Verteporfin. Journal of Biological Chemistry, 2011, 286, 7290-7300.	1.6	116
36	Identification of Pyruvate Kinase in Methicillin-Resistant Staphylococcus aureus as a Novel Antimicrobial Drug Target. Antimicrobial Agents and Chemotherapy, 2011, 55, 2042-2053.	1.4	42

#	Article	IF	CITATIONS
37	Asymmetric [³ H]â€labeling using ruthenium catalyzed transfer hydrogenation. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 205-207.	0.5	4
38	The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 887-892.	1.0	22
39	The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5502-5505.	1.0	22
40	Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6387-6393.	1.0	35
41	Design and synthesis of an all-in-one 3-(1,1-difluoroprop-2-ynyl)-3H-diazirin-3-yl functional group for photo-affinity labeling. Bioorganic and Medicinal Chemistry, 2009, 17, 5388-5395.	1.4	35
42	Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5266-5269.	1.0	2
43	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 923-928.	1.0	419
44	Design, synthesis, and biological evaluation of 8-biarylquinolines: A novel class of PDE4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1407-1412.	1.0	12
45	Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2023-2027.	1.0	14
46	Discovery of a Potent and Selective Prostaglandin D2 Receptor Antagonist, [(3R)-4-(4-Chloro-) Tj ETQq0 0 0 rgB Journal of Medicinal Chemistry, 2007, 50, 794-806.	T /Overloc 2.9	k 10 Tf 50 38 173
47	In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 301-304.	1.0	11
48	Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: Impacts of glutathione trapping and glucuronide conjugation on covalent binding. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3038-3043.	1.0	29
49	L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. Biochemical Pharmacology, 2007, 73, 1971-1981.	2.0	27
50	The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Experimental Cell Research, 2007, 313, 2969-2979.	1.2	69
51	Identification of an indole series of prostaglandin D2 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3043-3048.	1.0	20
52	Lack of Clinical Efficacy of a Phosphodiesterase-4 Inhibitor for Treatment of Heaves in Horses. Journal of Veterinary Internal Medicine, 2006, 20, 175.	0.6	11
53	Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: Structure–activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5241-5246.	1.0	30
54	Design and Synthesis of Tri-Ring P3Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K. Journal of Medicinal Chemistry, 2005, 48, 7520-7534.	2.9	99

#	Article	IF	CITATIONS
55	Discovery and Synthesis of a Potent, Selective and Orally Bioavailable EP4 Receptor Agonist. Heterocycles, 2004, 64, 437.	0.4	56
56	Substituted 2-Pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1923-1926.	1.0	16
57	Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1129-1132.	1.0	76
58	Optimization of a Tertiary Alcohol Series of Phosphodiesterase-4 (PDE4) Inhibitors:Â Structureâ^'Activity Relationship Related to PDE4 Inhibition and Human Ether-a-go-go Related Gene Potassium Channel Binding Affinity. Journal of Medicinal Chemistry, 2003, 46, 2413-2426.	2.9	70
59	Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone, 2002, 30, 159-163.	1.4	55
60	Discovery of L-791,943: A potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1457-1461.	1.0	54
61	Stereoselective Total Synthesis of (±)-Thielocin Alβ. Journal of the American Chemical Society, 2001, 123, 11381-11387.	6.6	26
62	5 Discovery of Montelukast: a Once-a-Day Oral Antagonist of Leukotriene D4 for the Treatment of Chronic Asthma. Progress in Medicinal Chemistry, 2001, 38, 249-277.	4.1	8
63	Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxxâ,,¢). Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2683-2686.	1.0	40
64	Importance of biodiversity to the modern pharmaceutical industry. Pure and Applied Chemistry, 1999, 71, 1655-1661.	0.9	16
65	Solid phase parallel synthesis of highly substituted thiophene derivatives and identification of novel phosphodiesterase-4 (PDE-4) inhibitors. Tetrahedron, 1999, 55, 11669-11685.	1.0	25
66	Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorganic and Medicinal Chemistry, 1999, 7, 901-919.	1.4	86
67	Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized?. European Journal of Medicinal Chemistry, 1999, 34, 671-685.	2.6	128
68	Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1255-1260.	1.0	253
69	2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2777-2782.	1.0	129
70	Heteroaromatic Dithioacetals Part I: The Preparation of Unsymmetrical Dithioacetals from Heteroaromatic Thiols. Synlett, 1998, 1998, 289-291.	1.0	6
71	Substituted (Pyridylmethoxy)naphthalenes as Potent and Orally Active 5-Lipoxygenase Inhibitors:Â Synthesis, Biological Profile, and Pharmacokinetics of L-739,010. Journal of Medicinal Chemistry, 1997, 40, 2866-2875.	2.9	28
72	Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. British Journal of Pharmacology, 1997, 121, 105-117.	2.7	287

#	Article	IF	CITATIONS
73	Silicon directed ipso-substitution of polymer bound arylsilanes: Preparation of biaryls via the Suzuki cross-coupling reaction. Tetrahedron Letters, 1996, 37, 2703-2706.	0.7	120
74	Single-Step Preparation of 1-Hydroxybisphosphonates via Addition of Dialkyl Phosphite Potassium Anions to Acid Chlorides. Journal of Organic Chemistry, 1995, 60, 5209-5213.	1.7	64
75	Synthesis of an [1251]-labelled derivative of MK-571, a tool for LTD4 receptor studies. Journal of Labelled Compounds and Radiopharmaceuticals, 1994, 34, 537-544.	0.5	1
76	Practical total synthesis of a naturally occurring thielocin via the regioselective arylation of a cyclic boronate. Tetrahedron Letters, 1994, 35, 7747-7750.	0.7	16
77	Enhancement of mass spectrometric detection of LTC4, LTD4, and LTE4 by derivatization. Journal of the American Society for Mass Spectrometry, 1994, 5, 292-298.	1.2	9
78	5-Lipoxygenase. Annual Review of Biochemistry, 1994, 63, 383-417.	5.0	399
79	Total synthesis of (.+)-thielocin A1.beta.: a novel inhibitor of phospholipase A2. Journal of the American Chemical Society, 1994, 116, 759-760.	6.6	50
80	Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase. Journal of Medicinal Chemistry, 1992, 35, 1299-1318.	2.9	30
81	Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Canadian Journal of Physiology and Pharmacology. 1992. 70. 799-807.	0.7	107
82	Diastereoselective alkylation of carbanions derived from 1,3-oxathianes. Tetrahedron Letters, 1992, 33, 725-728.	0.7	22
83	Mouse monoclonal antibody to a latent epitope of leucocyte receptors for leukotriene B4. Immunology, 1992, 76, 122-8.	2.0	4
84	Pharmacology of the leukotriene antagonist verlukast: The (R)-enantiomer of MK-571. Canadian Journal of Physiology and Pharmacology, 1991, 69, 1847-1854.	0.7	19
85	Stereoselective reduction of .gammaoxobutanoic acids using DIBAL-H and zinc chloride. Journal of Organic Chemistry, 1991, 56, 3083-3089.	1.7	28
86	Conformational Analysis of Leukotrienes and Related Compounds for Mapping the Leukotriene D4 Receptor: Application to the Design of Novel Anti-Asthma Drugs. , 1991, , 303-307.		0
87	Synthesis of [35s]-labelled MK-0571, a potent antagonist of LTD4. Journal of Labelled Compounds and Radiopharmaceuticals, 1990, 28, 297-306.	0.5	4
88	Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D ₄ receptor antagonist. Canadian Journal of Physiology and Pharmacology, 1989, 67, 17-28.	0.7	263
89	Asymmetric Dithioacetals III: The Preparation of the Enantiomers of Acid (L-660,711) (MK-571), an Antagonist of Leukotriene D4. Heterocycles, 1989, 28, 967.	0.4	13
90	The Development of New Antileukotriene Drugs: Specific Leukotriene D4 Antagonists and 5-Lipoxygenase Inhibitors. Advances in Experimental Medicine and Biology, 1989, 259, 75-108.	0.8	1

#	Article	IF	CITATIONS
91	L-648, 051, A Potent and Specific Aerosol Active Leukotriene D4 Antagonist. , 1988, 23, 113-119.		2
92	Stereoselective reduction of .gammaoxobenzenebutanoic acids. Journal of Organic Chemistry, 1987, 52, 304-307.	1.7	20
	Stereoselective Determination of (βS,γR and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 672 Td (βR,γS)-4-[3	-(4-Acetyl-	-3-hydroxy-2
93	Human and Rat Plasma by Normal-Phase High-Performance Liquid Chromatography. Journal of Pharmaceutical Sciences. 1987. 76. 169-173.	1.6	5
94	Design and synthesis of sodium (.beta.R*,.gamma.S*)-4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]gammahydroxybetamethylbenze a novel, selective, and orally active receptor antagonist of leukotriene D4. Journal of Medicinal Chemistry, 1986, 29, 1573-1576.	enebutanc 2.9	oate: 17
95	Stereoselective synthesis of some acetylenic analogues of leukotrienes A and D. Tetrahedron Letters, 1986, 27, 539-542.	0.7	13
96	Development of enzyme-linked immunosorbent assays for measurement of leukotrienes and prostaglandins. Journal of Immunological Methods, 1985, 81, 169-185.	0.6	36
97	The development of sensitive and specific radioimmunoassays for leukotrienes. Prostaglandins, Leukotrienes, and Medicine, 1984, 13, 21-25.	0.8	73
98	Preparation and stereochemistry of 8- and 9-hydroxy-2,5-ethano-3-benzazocines. Canadian Journal of Chemistry, 1983, 61, 2177-2182.	0.6	5
99	Studies on the conjugation of leukotriene B4 with proteins for development of a radioimmunoassay for leukotriene B4. Prostaglandins, 1983, 26, 605-613.	1.2	19
100	Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. Journal of Immunology, 1983, 131, 429-33.	0.4	144
101	Studies on the preparation of conjugates of leukotriene C4 with proteins for development of an immunoassay for SRS-A (1). Prostaglandins, 1982, 23, 603-613.	1.2	31
102	Synthesis and stereochemistry of 11-substituted 5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctenes. Journal of Organic Chemistry, 1982, 47, 4329-4334.	1.7	7
103	Preparation and analgesic properties of amino acid derivatives of (-)-5,9.alphadiethyl-2'-hydroxybenzomorphan. Journal of Medicinal Chemistry, 1981, 24, 1297-1299.	2.9	5
104	Synthesis of β-Trimethylsilyloxythioethers and β-Hydroxythioethers by the Reaction of Epoxides with Aryl- and Alkylthiotrimethylsilanes. Synthetic Communications, 1981, 11, 391-398.	1.1	34
105	The synthesis of leukotrienes. Progress in Lipid Research, 1981, 20, 905-907.	5.3	3
106	Synthesis of leukotrienes - new synthesis of natural leukotriene A4. Tetrahedron Letters, 1981, 22, 979-982.	0.7	52
107	The preparation of octahydro leukotrienes C, D, and E via a stereoselective sulfenyllactonization reaction. Tetrahedron Letters, 1981, 22, 4933-4936.	0.7	30
108	The synthesis of a leukotriene with SRS-like activity. Tetrahedron Letters, 1980, 21, 1485-1488.	0.7	108

#	Article	IF	CITATIONS
109	The chemistry of thujone. II. Insect juvenile hormone analogues via acid dianion coupling. The β lactone route. Canadian Journal of Chemistry, 1979, 57, 3145-3154.	0.6	9
110	The chemistry of thujone. Bioorganic Chemistry, 1978, 7, 289-302.	2.0	8
111	Reaction of γ-Haloketones with Sodium-Potassium Alloy; A New Fragmentation Reaction. Synthesis, 1975, 1975, 428-430.	1.2	6
112	Conversion of alcohols into amides using chlorodiphenylmethylium hexachloroantimonate in nitrile solvents. Journal of the Chemical Society Chemical Communications, 1973, , 331.	2.0	20
113	Novel epoxides from Thamnosma Montana Torr. and Frem Tetrahedron Letters, 1969, 10, 1845-1847.	0.7	12